Artificial Diets with Selective Restriction of Amino Acids and Very Low Levels of Lipids Induce Anticancer Activity in Mice with Metastatic Triple-Negative Breast Cancer

Author:

Guillén-Mancina Emilio1,Jiménez-Alonso Julio José1ORCID,Calderón-Montaño José Manuel1ORCID,Jiménez-González Víctor1,Díaz-Ortega Patricia1,Burgos-Morón Estefanía1ORCID,López-Lázaro Miguel1ORCID

Affiliation:

1. Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Sevilla, Spain

Abstract

Patients with metastatic triple negative breast cancer (TNBC) need new therapies to improve the low survival rates achieved with standard treatments. In this work, we show for the first time that the survival of mice with metastatic TNBC can be markedly increased by replacing their normal diet with artificial diets in which the levels of amino acids (AAs) and lipids are strongly manipulated. After observing selective anticancer activity in vitro, we prepared five artificial diets and evaluated their anticancer activity in a challenging model of metastatic TNBC. The model was established by injecting 4T1 murine TNBC cells into the tail vein of immunocompetent BALB/cAnNRj mice. First-line drugs doxorubicin and capecitabine were also tested in this model. AA manipulation led to modest improvements in mice survival when the levels of lipids were normal. Reducing lipid levels to 1% markedly improved the activity of several diets with different AA content. Some mice fed the artificial diets as monotherapy lived much longer than mice treated with doxorubicin and capecitabine. An artificial diet without 10 non-essential AAs, with reduced levels of essential AAs, and with 1% lipids improved the survival not only of mice with TNBC but also of mice with other types of metastatic cancers.

Funder

AMINOVITA, S.L.

Junta de Andalucía

University of Seville through the “VI Plan Propio de Investigación y Transferencia”

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference73 articles.

1. Cancer Statistics;Siegel;CA Cancer J. Clin.,2022

2. National Cancer Institute (2022, October 14). Surveillance, Epidemiology, and End Results Program-Breast Cancer Survival Statistics, Available online: https://seer.cancer.gov/statistics-network/explorer/application.html?site=55&data_type=4&graph_type=5&compareBy=stage&chk_stage_104=104&chk_stage_105=105&chk_stage_106=106&chk_stage_107=107&series=9&sex=3&race=1&age_range=1&advopt_precision=1&advopt_show_.

3. Triple-Negative Breast Cancer Has Worse Overall Survival and Cause-Specific Survival than Non-Triple-Negative Breast Cancer;Li;Breast Cancer Res. Treat.,2017

4. National Comprehensive Cancer Network (2022, October 14). NCCN Guidelines Version 4.2022 Breast Cancer. Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419.

5. Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer;Tutt;N. Engl. J. Med.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3